Neurocrine Biosciences (NBIX) Cash from Operations Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 425.00% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 450.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.00% |
| Dec 31, 2025 | 60.16% |
| Sep 30, 2025 | 43.99% |
| Jun 30, 2025 | 57.89% |
| Mar 31, 2025 | -50.27% |
| Dec 31, 2024 | 96.36% |
| Sep 30, 2024 | -25.47% |
| Jun 30, 2024 | -64.03% |
| Mar 31, 2024 | 204.07% |
| Dec 31, 2023 | -13.64% |
| Sep 30, 2023 | 114.57% |
| Jun 30, 2023 | 30.05% |
| Mar 31, 2023 | -209.14% |
| Dec 31, 2022 | 3,304.76% |
| Sep 30, 2022 | 59.87% |
| Jun 30, 2022 | 33.82% |
| Mar 31, 2022 | -146.39% |
| Dec 31, 2021 | -95.56% |
| Sep 30, 2021 | 402.94% |
| Jun 30, 2021 | -13.20% |